225 related articles for article (PubMed ID: 15514703)
1. Biological effects of C1 inhibitor.
Davis AE
Drug News Perspect; 2004 Sep; 17(7):439-46. PubMed ID: 15514703
[TBL] [Abstract][Full Text] [Related]
2. Biological activities of C1 inhibitor.
Davis AE; Mejia P; Lu F
Mol Immunol; 2008 Oct; 45(16):4057-63. PubMed ID: 18674818
[TBL] [Abstract][Full Text] [Related]
3. C1 inhibitor, a multi-functional serine protease inhibitor.
Davis AE; Lu F; Mejia P
Thromb Haemost; 2010 Nov; 104(5):886-93. PubMed ID: 20806108
[TBL] [Abstract][Full Text] [Related]
4. The pathophysiology of hereditary angioedema.
Davis AE
Clin Immunol; 2005 Jan; 114(1):3-9. PubMed ID: 15596403
[TBL] [Abstract][Full Text] [Related]
5. The pathogenesis of hereditary angioedema.
Davis AE
Transfus Apher Sci; 2003 Dec; 29(3):195-203. PubMed ID: 14572810
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of C1-inhibitor deficiency.
Pappalardo E; Zingale LC; Terlizzi A; Zanichelli A; Folcioni A; Cicardi M
Immunobiology; 2002 Sep; 205(4-5):542-51. PubMed ID: 12396014
[TBL] [Abstract][Full Text] [Related]
7. C1 inhibitor: molecular and clinical aspects.
Cicardi M; Zingale L; Zanichelli A; Pappalardo E; Cicardi B
Springer Semin Immunopathol; 2005 Nov; 27(3):286-98. PubMed ID: 16267649
[TBL] [Abstract][Full Text] [Related]
8. The Role of Complement in Hereditary Angioedema.
Levi M; Cohn DM
Transfus Med Rev; 2019 Oct; 33(4):243-247. PubMed ID: 31676220
[TBL] [Abstract][Full Text] [Related]
9. Complement, Kinins, and Hereditary Angioedema: Mechanisms of Plasma Instability when C1 Inhibitor is Absent.
Kaplan AP; Joseph K
Clin Rev Allergy Immunol; 2016 Oct; 51(2):207-15. PubMed ID: 27273087
[TBL] [Abstract][Full Text] [Related]
10. The plasma bradykinin-forming pathways and its interrelationships with complement.
Kaplan AP; Ghebrehiwet B
Mol Immunol; 2010 Aug; 47(13):2161-9. PubMed ID: 20580091
[TBL] [Abstract][Full Text] [Related]
11. Hereditary and acquired C1-inhibitor-dependent angioedema: from pathophysiology to treatment.
Zeerleder S; Levi M
Ann Med; 2016; 48(4):256-67. PubMed ID: 27018196
[TBL] [Abstract][Full Text] [Related]
12. C1 inhibitor: biologic activities that are independent of protease inhibition.
Davis AE; Cai S; Liu D
Immunobiology; 2007; 212(4-5):313-23. PubMed ID: 17544816
[TBL] [Abstract][Full Text] [Related]
13. Role of the P2 residue of complement 1 inhibitor (Ala443) in determination of target protease specificity: inhibition of complement and contact system proteases.
Zahedi R; Wisnieski J; Davis AE
J Immunol; 1997 Jul; 159(2):983-8. PubMed ID: 9218620
[TBL] [Abstract][Full Text] [Related]
14. [Activation of plasma cascade systems in sepsis: role of C1 inhibitors].
Zeerleder S; Caliezi C; Redondo M; Devay J; Wuillemin WA
Schweiz Med Wochenschr; 1999 Oct; 129(39):1410-7. PubMed ID: 10542999
[TBL] [Abstract][Full Text] [Related]
15. C1-Esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema.
Caliezi C; Wuillemin WA; Zeerleder S; Redondo M; Eisele B; Hack CE
Pharmacol Rev; 2000 Mar; 52(1):91-112. PubMed ID: 10699156
[TBL] [Abstract][Full Text] [Related]
16. Hereditary and acquired deficiencies of C1 inhibitor.
Davis AE
Immunodefic Rev; 1989; 1(3):207-26. PubMed ID: 2698641
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of vascular permeability by antisense-mediated inhibition of plasma kallikrein and coagulation factor 12.
Bhattacharjee G; Revenko AS; Crosby JR; May C; Gao D; Zhao C; Monia BP; MacLeod AR
Nucleic Acid Ther; 2013 Jun; 23(3):175-87. PubMed ID: 23582057
[TBL] [Abstract][Full Text] [Related]
18. Pathogenic mechanisms of bradykinin mediated diseases: dysregulation of an innate inflammatory pathway.
Kaplan AP; Joseph K
Adv Immunol; 2014; 121():41-89. PubMed ID: 24388213
[TBL] [Abstract][Full Text] [Related]
19. Complement regulatory protein C1 inhibitor binds to selectins and interferes with endothelial-leukocyte adhesion.
Cai S; Davis AE
J Immunol; 2003 Nov; 171(9):4786-91. PubMed ID: 14568956
[TBL] [Abstract][Full Text] [Related]
20. C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2.
Hack CE; Ogilvie AC; Eisele B; Eerenberg AJ; Wagstaff J; Thijs LG
Intensive Care Med; 1993; 19 Suppl 1():S19-28. PubMed ID: 8053997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
